Comparative study of neuroprotective effects of ulinastatin versus piracetam treating on acute traumatic craniocerebral injury

To evaluate the clinical efficacy and feasibility a pplication of a human urinary protease inhibitor (U linastatin, UTI) for the patients with acute severe traumatic cranio cerebral injury. 90 cases with acute severe traumatic craniocerebral injury were randomly divided into th e Ulinastatin treatment group (45 cases) and the co ntrol group (45 cases), the control group received piracetam tr eatment. Ulinastatin conventional therapy in the tr ea ment group based on the intravenous injection of Ulinastatin 2 00000U, 2 times per day, 12 days a cycle, at the sa me time, piracetam treatment is based on the intravenous dri p piracetam 20ml:4g, 2times/d, 12 days a cycle. The clinical effects was assessed with the GCS and MMSE score sh eet at the 12th day and the GOS score sheet at 6 mo nths after craniocerebral injury. Record the side effects and complications such as incidences of alimentary trac t hemorrhage, liver damage and renal function injury. Comparing t he treatment group with the control group, GCS scor e and MMSE score had significant difference (P<0.05), 6 m onths GOS score of the neurological function recove ry in the treatment group was significantly better than that in the control group(P<0.05). Ulinastatin not only appears the effective treatment and promotes the neurological f unction recovery, but also reduces the risk of deat h for the patients with severe traumatic craniocerebral injur y. Ulinastatin is safe and reliable treating on the patients with acute severe traumatic craniocerebral injury.